From the Journals

‘Genetic’ height linked to peripheral neuropathy and certain skin and bone infections


 

FROM PLOS GENETICS

What does it all mean?

“Genetic height is in your genes – there is nothing to be done about it – so it is more of academic interest than clinical interest,” Dr. Wilson said. It’s not even clear whether incorporating a person’s height – actual or genetically predicted, if it could be easily determined for each person – into risk calculators. ”To know whether it would be beneficial to use height (or genetic height) as a risk factor, you’d need to examine each condition of interest, adjusting for all known risk factors, to see if height improved the prediction,” Dr. Wilson said. “I suspect for most conditions, the well-known risk factors would swamp height. For example, high genetic height might truly increase risk for neuropathy. But diabetes might increase the risk so much more that height is not particularly relevant.”

On the other hand, the fact that height in general has any potential influence at all on disease risk may inspire physicians to consider other risk factors in especially tall individuals.

”Physicians may find it interesting that we have some confirmation that height does increase the risk of certain conditions,” Dr. Wilson said. “While this is unlikely to dramatically change practice, they may be a bit more diligent in looking for other relevant risk factors for the diseases found in this study in their very tall patients.”

The research was funded by the U.S. Department of Veteran Affairs, the Boettcher Foundation’s Webb-Waring Biomedical Research Program, the National Institutes of Health, and a Linda Pechenik Montague Investigator award. One study coauthor is a full-time employee of Novartis Institutes of Biomedical Research. The other authors and Dr. Wilson had no disclosures.

*Correction, 6/29/22: An earlier version of this article misstated the average age of Black participants.

Pages

Recommended Reading

Seven hours of sleep is ideal for middle aged and older
Journal of Clinical Outcomes Management
FDA clears diagnostic test for early Alzheimer’s
Journal of Clinical Outcomes Management
Study casts doubt on safety, efficacy of L-serine supplementation for AD
Journal of Clinical Outcomes Management
Most COVID-19 survivors return to work within 2 years
Journal of Clinical Outcomes Management
Many Americans missing an opportunity to prevent dementia
Journal of Clinical Outcomes Management
Long COVID neuropsychiatric deficits greater than expected
Journal of Clinical Outcomes Management
Hearing, vision loss combo a colossal risk for cognitive decline
Journal of Clinical Outcomes Management
Blood-based assay may offer new way of diagnosing Parkinson’s disease
Journal of Clinical Outcomes Management
MS and COVID-19: Conflicting signs on risk but some trends are clearer
Journal of Clinical Outcomes Management
‘Sit less, move more’ to reduce stroke risk
Journal of Clinical Outcomes Management